Symptomatic resolution among chinese patients with schizophrenia and associated factors

Journal of the Formosan Medical Association

Volumn 109, Issue 5, 2010, Pages 378-388

  Li, Cheng Ta ^a,b   Su, Tung Ping ^a,b   Chou, Yuan Hwa ^a,b   Lee, Ying Chiao ^a,b   Liu, Mu En ^a   Ku, Hsiao Lun ^a   Shan, Ian Kai ^a   Bai, Ya Mei ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Antipsychotic agents; Remission; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

ADULT; AGE; ARTICLE; CHINESE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE SEVERITY; EDUCATIONAL STATUS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NEGATIVE SYNDROME; POSITIVE SYNDROME; PSYCHOLOGICAL WELL BEING; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REMISSION; SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL STATUS; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; AGED; ASIAN; ETHNOLOGY; MIDDLE AGED; ONSET AGE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; STATISTICS; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CLOZAPINE; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955862730     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60066-6     Document Type: Article

References (47)

1. Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry 2005;50:892-900. (Pubitemid 43161743)
2. Amminger GP, Resch F, Mutschlechner R, et al. Premorbid adjustment and remission of positive symptoms in firstepisode psychosis. Eur Child Adolesc Psychiatry 1997;6: 212-8.
3. Curtis CE, Calkins ME, Grove WM, et al. Saccadic disinhibition in patients with acute and remitted schizophrenia and their first-degree biological relatives. Am J Psychiatry 2001;158:100-6. (Pubitemid 32047253)
4. Eaton WW, Thara R, Federman E, et al. Remission and relapse in schizophrenia: the Madras Longitudinal Study. J Nerv Ment Dis 1998;186:357-63. (Pubitemid 28290027)
5. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-76. (Pubitemid 23143126)
6. Auslander LA, Jeste DV. Sustained remission of schizophrenia among community-dwelling older outpatients. Am J Psychiatry 2004;161:1490-3. (Pubitemid 38989106)
7. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry2006;39:161-70.
8. Andreasen NC, Carpenter WT, Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-9. (Pubitemid 40343909)
9. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. (Pubitemid 18039085)
10. Helldin L, Kane JM, Karilampi U, et al. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res 2006;40:738-45. (Pubitemid 44486248)
11. Helldin L, Kane JM, Karilampi U, et al. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res 2007;93:160-8. (Pubitemid 46817925)
12. van Os J, Drukker M, A Campo J, et al. Validation of remission criteria for schizophrenia. Am J Psychiatry2006;163:2000-2. (Pubitemid 44807793)
13. Docherty JP, Bossie CA, Lachaux B, et al. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol 2007;22:51-5. (Pubitemid 44950768)
14. Lasser RA, Nasrallah H, Helldin L, et al. Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr Res 2007;96:223-31. (Pubitemid 47505218)
15. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007;89:129-39. (Pubitemid 44881311)
16. De Hert M, van Winkel R, Wampers M, et al. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007;92:68-73. (Pubitemid 46561226)
17. Peuskens J, Kaufman L, Van Vleymen B. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode. Schizophr Res 2007;95:169-73 (Pubitemid 47315739)
18. Lasser RA, Bossie CA, Gharabawi GM, et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005;77:215-27. (Pubitemid 41112215)
19. San L, Ciudad A, Alvarez E, et al. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a crosssectional study. Eur Psychiatry 2007;8:490-8 (Pubitemid 350087651)
20. Zimmermann PaF B. Test for Attentional Performance (TAP). Psytest Press, Freiburg, 1997.
21. Liu SK, Chiu CH, Chang CJ, et al. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers. Am J Psychiatry 2002; 159:975-82. (Pubitemid 34586943)
22. Tsuang HC, Lin SH, Liu SK, et al. More severe sustained attention deficits in nonpsychotic siblings of multiplex schizophrenia families than in those of simplex ones. Schizophr Res 2006;87:172-80. (Pubitemid 44428112)
23. Krishnadas R, Moore BP, Nayak A, et al. Relationship of cognitive function in patients with schizophrenia in remission to disability: a cross-sectional study in an Indian sample. Ann Gen Psychiatry 2007;6:19.
24. Hintze B, Kuhn-Dymecka A, Bembenek A, et al. Attention impairment in patients suffering from schizophrenia and their relatives of first-degree. Psychiatr Pol 2004;38: 861-73. [In Polish] (Pubitemid 39407198)
25. Liu SK, Chen WJ, Chang CJ, et al. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacology 2000;22:311-9. (Pubitemid 30089542)
26. th Edition. Washington: American Psychiatric Association, 1994.
27. Cheng JJ, Ho H, Chang CJ, et al. Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Chin Psychiatry 1996;10:251-8.
28. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100. (Pubitemid 17115352)
29. Psychopharmacology Research Branch NIoMH. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976.
30. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-9.
31. Jenkinson C, Layte R, Jenkinson D, et al. A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies? J Public Health Med 1997; 19:179-86. (Pubitemid 27316478)
32. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88. (Pubitemid 32510889)
33. Sim K, Chuan Su H, Fujii S, et al. Low doses of antipsychotic drugs for hospitalized schizophrenia patients in East Asia: 2004 vs. 2001. Int J Neuropsychopharmacol2009;12:117-23.
34. Emsley RA, Roberts MC, Rataemane S, et al. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 2002;63:9-14. (Pubitemid 34113480)
35. Bhugra D. Severe mental illness across cultures. Acta Psychiatr Scand Suppl 2006;429:17-23. (Pubitemid 43340883)
36. San L, Ciudad A, Alvarez E, et al. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a crosssectional study. Eur Psychiatry 2007;22:490-8. (Pubitemid 350087651)
37. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21:911-36. (Pubitemid 47557106)
38. Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl 2007;50:S64-70. (Pubitemid 47204558)
39. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 2007;68:e04.
40. Sharif Z. Side effects as influencers of treatment outcome. J Clin Psychiatry 2008;69(Suppl 3):38-43.
41. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
42. Ciudad A, Alvarez E, Bobes J, et al. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr Res 2009;108:214-22.
43. Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008;8:31.
44. Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother 2006;7:1739-48.
45. van Os J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006; 113:91-5. (Pubitemid 43348370)
46. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 2009;70:717-29.
47. Szoke A, Trandafir A, Dupont ME, et al. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 2008;192:248-57. (Pubitemid 351692396)